This report analyzes the worldwide markets for Bulk Paclitaxel in kilograms and US$ Million. The report provides separate comprehensive analytics for the US, and Rest of World. Annual forecasts are provided for the period of 2000 through 2015. The report profiles 35 companies including many key and niche players worldwide such as Abraxis BioScience, Inc., Bioxel Pharma, Inc., Bristol-Myers Squibb Co., Hospira, Inc., Indena S.p.A., OncoGenex Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., and Xechem International Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

I. Introduction, Methodology & Product Definitions
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study
II. Executive Summary
- 1. Industry Overview I
  - Paclitaxel - Leading from the Front I
  - US Market - Magnificently Outdistancing Others I
  - Cancer Blockbusters - Facing the Brunt I
  - A Sunrise Opportunity I
  - BMS' Reign Comes to an End I
  - Exploring New Avenues I
  - Falling Prices - Boon for The Customers, Bane for The Companies I
  - All the Strangle for Peanuts? I
  - Factors Affecting the Market I
  - Paclitaxel Versus Abraxane I
- 2. Outlook I
  - Bulk Paclitaxel - Great Future Ahead I
  - Competitive Scenario I
  - Cancer Generics - A Time for Optimism I
  - The US Piazza I
- 3. Product Overview I
  - Chemical Properties I
  - Sourcing I
  - from Natural Sources I
  - Yew Trees I
  - from Semi-Synthesis Process I
  - Mechanism of Action I
  - History of Paclitaxel and its Discovery as an Anti-Cancer Agent I
  - China Wins Laurels for Supply of Natural Paclitaxel II-1
  - Hazelnut Trees Emerge as the Alternate Source of Paclitaxel II-1
  - Taxol - The Uncrowned Leader... II-1
  - Paclitaxel - Concerns II-1
  - Abraxane and Tocosol: Set to Ride the Market Duel? II-1
  - Many Faces (Phases) of Paclitaxel - The Variants II-1
  - Taxotere - A Potential Competitor to Paclitaxel II-1
- 4. Research and Development II-1
  - Angiotech Unfurls New Dimensions for Paclitaxel II-1
  - Clinical Research Favors Paclitaxel for Breast Cancer Treatment II-1
  - American BioScience' Nab Technology Unveils Higher Tissue Penetration Potential II-1
  - Naturol Develops Unique Extraction Technology for Producing Paclitaxel from Canadian Yew II-1
  - Ivax Corp.'s Xorane Revolutionizes the Delivery of Paclitaxel II-1
- 5. Product Launches/Introductions II-1
  - Dabur Launches Cancer Drug. II-1
  - Dabur Introduces Nanoxel. II-1
  - Nippon Introduces Paclitaxel Injection NK. II-1
- 6. Recent Industry Activity II-1
  - Sonus to Merge with OncoGenex . II-1
  - Acusphere Signs Licensing Deal with Cephalon . II-1
  - Sonus Terminates TOCOSOL Paclitaxel Development Program . II-1
  - Eagle Pharmaceuticals to Develop and Market Tocosol Paclitaxel . II-1
  - Pliva Lachema Receives ANDA for Paclitaxel Injection . II-1
  - Cell Therapeutics Receives EMEA Acceptance . II-1
  - Abraxis Wins Approval for ABRAXANE in Korea . II-1
  - Boston Scientific Obtains Approval for TAXUS Liberte from Health Canada . II-1
  - Cell Therapeutics Renames Xyotax as Opaxio. II-1
  - Hospira Takes over Mayne Pharma . II-1
  - Protherics to Acquire MacroMed . II-1
  - Abraxis Acquires Arizona Production Facility . II-1
  - Indena Inks Worldwide License Agreement with Spectrum Pharma . II-1
  - Bioxel Bags Major Paclitaxel Order . II-1
  - Bioxel Enters into Supply Agreement. II-1
  - Bioxel Bags Paclitaxel Supply Contract . II-1
  - Indena Establishes New Plant to Produce Synthetic Paclitaxel . II-1
  - Abraxis Selects Korean Green Cross to Market ABRAXANE . II-1
  - Abraxis Grants License to Biocon for Marketing ABRAXANE . II-1
  - Bioxel Registers Docetaxel with US FDA . II-1
  - Bayer Quashes TOCOSOL Paclitaxel License with Sonus . II-2
  - Abraxis' ABRAXANE Convinces European CHMP . II-2
  - Abraxis Receives Approval for ABRAXANE in Australia . II-2
  - Eurocor Receives CE Mark. II-2
  - SuperGen Divests Certain Drugs to Intas . II-2
  - Abraxis Plans Separation of Oncology Business. II-2
  - Teva Acquires IVAX II-2
  - Mayne to Acquire Nipent and SurfaceSafe Product Rights in North America II-2
  - Athersys Expands Research Collaboration with Bristol-Myers Squibb II-2
  - American Pharmaceutical Partners and American BioScience Combine to Create Abraxis BioScience II-2
  - Bioxel Increases its Presence in Europe II-2
  - Xechem Resolves Paclitaxel Antitrust Lawsuit with Bristol-Myers Squibb II-2
  - Angiotech Acquires American Medical Instruments II-2
  - Paxis Signs Supply Agreement for Europe and the United States II-2
  - Angiotech to Take over Quill Medical II-2
  - Bioxel and Cook Enters Supply Agreement for Paclitaxel II-2
  - Angiotech Acquires Lifespan Vascular Graft Business II-2
  - Bristol-Myers Extends Agreement with Ambit II-2
  - Angiotech Takes over Afmedica II-2
  - Bristol-Myers Squibb Gets European Approval for Paclitaxel II-2
  - Angiotech Signs Exclusive License Agreement with CABG Medical II-2
  - Conor Medsystems Acquires the Assets of Phytogen Life Sciences II-2
  - Sonus Pharmaceuticals and Schering Sign Licensing Agreement. II-2
  - Sonus' Tocosol Wins FDA's ODD II-2
  - ABI's Abraxane Wins FDA Approval II-2
  - SuperGen's Paclitaxel Injection Accorded ANDA Status from the USFDA II-2
  - Ivax Signs Agreement with Mayne II-2
  - Integrated Bio Pharma Acquires Hauser CRO II-2
  - Mayne Gearing up to Fight it Alone with Proprietary Paclitaxel II-2
  - Bioxel Inks a Paclitaxel Supply Deal with CTI II-2
  - DFB Pharmaceuticals Takes over Phyton II-2
  - NaPro Divests Paclitaxel Business to Faulding II-2
  - Bioxel-Aerojet's Large-Scale Paclitaxel Purification Process Gets FDA's Nod II-2
  - Ivax Earns Expanded Approval for Paxene from the European Commission II-2
  - Sonus Obtains Third Patent for the Composition of Tocosol Paclitaxel II-2
  - Bioxel Forays into the European Market II-2
  - Xechem Pockets Additional Patents for Second Generation Paclitaxel II-2
  - Dabur Pharma Initiates Phase IIb Trial for Nanoparticle Delivery Systems II-2
  - Acusphere Inc. Completes Phase 1 Trial for AI-850 II-2
  - Tisorex Changes Name to Paxis Pharmaceuticals II-2
- 7. Focus on Select Global Players II-2
  - Abraxis BioScience, Inc. (USA) II-2
  - Bioxel Pharma Inc. (Canada) II-2
  - Bristol-Myers Squibb Co. (USA) II-2
  - Hospira, Inc. (USA) . II-2
  - Indena S.p.A. (Italy) II-2
  - OncoGenex Pharmaceuticals, Inc. (USA). II-2
  - Teva Pharmaceuticals USA, Inc. (USA) . II-2
  - Xechem International Inc. (USA) II-3
- 8. Global Market Perspective II-3
III. Market
- 1. The United States II
  - A. Market Analysis II
    - Current and Future Analysis II
    - Rising Demand for Paclitaxel II
    - Alarming Growth of Breast Cancer II
    - Clinical Research Favors Paclitaxel for Breast Cancer Treatment II
    - Paclitaxel - An Important Element II
    - Corporate Talk II
    - Drug-Eluting Stents - Marching Ahead II
    - Strategic Corporate Developments II
    - Key Players II
  - B. Market Analytics III-1
- 2. Rest of World III-1
  - A. Market Analysis III-1
    - Current and Future Analysis III-1
    - Europe. III-1
    - European Market Overview III-1
    - European Market Battling Cost-Containment Woes III-1
    - Efforts to Improve the Scenario and their Effect on Paclitaxel Market III-1
    - China. III-1
    - Chinese Government Strategizing to save Paclitaxel Reserves III-1
    - Product Launches/Developments. III-1
    - Strategic Corporate Development III-1
    - Key Players III-2
  - B. Market Analytics III-2
IV. Competitive Landscape
List of Tables
- Table 1: World Recent past, Current & Future Analysis for Bulk Paclitaxel by Geographic Region - US and Rest of World Markets Independently Analyzed with Annual Sales in Kilograms for Years 2000 through 2010 (includes corresponding Graph/Chart). II-3
- Table 2: World Long-term Projections for Bulk Paclitaxel by Geographic Region - US and Rest of World Markets Independently Analyzed with Annual Sales in Kilograms for Years 2011 through 2015 (includes corresponding Graph/Chart). II-3
- Table 3: World Recent past, Current & Future Analysis for Bulk Paclitaxel by Geographic Region - US and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart). II-3
- Table 4: World Long-term Projections for Bulk Paclitaxel by Geographic Region - US and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart). II-3
- Table 5: World 10-Year Perspective for Bulk Paclitaxel by Geographic Region - Percentage Breakdown by Volume Sales for US and Rest of World Markets for Years 2003, 2008, & 2012. II-3
- Table 6: World 10-Year Perspective for Bulk Paclitaxel by Geographic Region - Percentage Breakdown by Dollar Sales for US and Rest of World Markets for Years 2003, 2008, & 2012. II-3
- Table 7: US Recent past, Current & Future Analysis for Bulk Paclitaxel Market with Annual Sales in Kilograms for Years 2000 through 2010 (includes corresponding Graph/Chart) III-1
- Table 8: US Long-term Projections for Bulk Paclitaxel Market with Annual Sales in Kilograms for Years 2011 through 2015.(includes corresponding Graph/Chart) III-1
- Table 9: US Recent past, Current & Future Analysis for Bulk Paclitaxel Market with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-1
- Table 10: US Long-term Projections for Bulk Paclitaxel Market with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart). III-1
- Table 11: Rest of World Recent past, Current & Future Analysis for Bulk Paclitaxel Market with Annual Sales in Kilograms for Years 2000 through 2010 (includes corresponding Graph/Chart) III-2
- Table 12: Rest of World Long-term Projections for Bulk Paclitaxel with Annual Sales in Kilograms for Years 2011 through 2015 (includes corresponding Graph/Chart). III-2
- Table 13: Rest of World Recent past, Current & Future Analysis for Bulk Paclitaxel Market with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-2
- Table 14: Rest of World Long-term Projections for Bulk Paclitaxel Market with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart). III-2

Pharmaceutical Market Research

Bulk Paclitaxel

Bulk Paclitaxel

Contents

Related products